Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin

Nephrology Dialysis Transplantation

Volumn 12, Issue 12, 1997, Pages 2801-2802

  Al Hawas, F ^a   Abdalla, A H ^a   Popovich, W ^a   Mousa, D H ^a   Al Sulaiman, M H ^a   Al Khader, A A ^a  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; CLINICAL ARTICLE; DRUG SAFETY; ERYTHROPOIESIS; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LETTER; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0030716321     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/12.12.2801     Document Type: Letter

References (4)

1. Kalantar-Zadeh C., Hoffken B., Wunsch H., Fink H., Kleiner M., Luft F. C. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26(2): 292-299
2. Muirhead N., Bargmann J., Burgess E. et al. Evidence based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995; 26(2) [Suppl. 1]: S1-S24
3. Fourtounas C, Kavadias D, Tsouknikas J, Barboutis K. Iron deficiency during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 1994; 735-736
4. Fishbane S., Frei G. L., Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26(1 ): 41-46